scholarly journals Patient‐reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a population‐based prospective cohort

Cancer ◽  
2019 ◽  
Vol 125 (20) ◽  
pp. 3657-3665 ◽  
Author(s):  
Brandon T. Mullins ◽  
Ramsankar Basak ◽  
James R. Broughman ◽  
Ronald C. Chen
PLoS ONE ◽  
2014 ◽  
Vol 9 (7) ◽  
pp. e103496 ◽  
Author(s):  
Parashar Pravin Ramanuj ◽  
Julia Granerød ◽  
Nicholas W. S. Davies ◽  
Stefano Conti ◽  
David W. G. Brown ◽  
...  

Cancer ◽  
2016 ◽  
Vol 123 (1) ◽  
pp. 138-143 ◽  
Author(s):  
Jordan A. Holmes ◽  
Jeannette T. Bensen ◽  
James L. Mohler ◽  
Lixin Song ◽  
Merle H. Mishel ◽  
...  

2011 ◽  
Vol 93 (4) ◽  
pp. 281-285 ◽  
Author(s):  
Andras Zaborszky ◽  
Rita Gyanti ◽  
John A Barry ◽  
Brian K Saxby ◽  
Panchanan Bhattacharya ◽  
...  

INTRODUCTION The NHS is required to collect data from patient reported outcome measures (PROMs) for inguinal hernia surgery. We explored the use of one such measure, the Carolinas Comfort Scale® (CCS), to compare long-term outcomes for patients who received two different types of mesh. The CCS questionnaire asks about mesh sensation, pain and movement limitations, and combines the answers into a total score. PATIENTS AND METHODS A total of 684 patients were treated between January 2007 and August 2008 and were followed up in November 2009. RESULTS Data on 215 patients who met the inclusion criteria were available (96 patients who received Surgipro™ mesh and 119 who received Parietene™ Progrip™ mesh). Recurrence rates were similar in the Surgipro™ group (2/96, 2.1%) and Progrip™ group (3/118, 2.5%) (Fisher's exact test = 1.0). Chronic pain occurred less frequently in the Surgipro™ group (11/95, 11.6%) than in the Progrip™ group (22/118, 18.6%) (p<0.157). Overall, 90% of CCS total scores indicated a good outcome (scores of 10 or less out of 115). A principal component analysis of the CCS found that responses clustered into two subscales: ‘mesh sensation’ and ‘pain+movement limitations’. The Progrip™ group had a slightly higher mesh sensation score (p<0.051) and similar pain+movement limitations scores (p<0.120). CONCLUSIONS In this study of quality of life outcomes related to different mesh types, the CCS subscales were more sensitive to differences in outcome than the total CCS score for the whole questionnaire. Future research should consider using the CCS subscales rather than the CCS total score.


1999 ◽  
Vol 6 (2) ◽  
pp. 78-86 ◽  
Author(s):  
YOICHI ARAI ◽  
KAZUTOSHI OKUBO ◽  
YOSHITAKA AOKI ◽  
SHINYA MAEKAWA ◽  
TAKASHI OKADA ◽  
...  

2017 ◽  
Vol 121 (4) ◽  
pp. 540-548 ◽  
Author(s):  
Pierre Blanchard ◽  
John W. Davis ◽  
Steven J. Frank ◽  
Jeri Kim ◽  
Curtis A. Pettaway ◽  
...  

2010 ◽  
Vol 183 (4) ◽  
pp. 1464-1468 ◽  
Author(s):  
Michael A. Liss ◽  
Kathryn Osann ◽  
Noah Canvasser ◽  
William Chu ◽  
Alexandra Chang ◽  
...  

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 143-143
Author(s):  
Jeremy L. Millar ◽  
Susan M. Evans ◽  
Mark Frydenberg ◽  
Declan G. Murphy ◽  
Damien M. Bolton ◽  
...  

143 Background: We aimed to use a population based quality registry established in Australia, to review patient-reported health-related QOL after the diagnosis of Prostate Cancer (PCa). Methods: Prospective registry of men with PCa from statutory notifications to the canonical population-based cancer registry in Victoria. An "opt-off" mechanism used. Coverage expanded from 30%-80% of State population over time. Demographics and disease features, management, and outcomes from medical record; men phoned at 12 and 24 months (m), interviewed with script including SF12 and items from standard form (UCLA PCI) for specific QOL outcomes. Urinary, rectal, and sexual function bother (UB, RB, and SB) scores where analysed by univariate and multivariable modelling for relationship of these with presentation or management factors, adjusting for risk. Results: Men from 8/2008 - 2/2011; 1.9% of eligible opted out. Followed 1172 to 12 & 24 m. Median diagnosis age 65 yr; median PSA 6.8 ng/mL; 97.3% clinically localised with 47.7% having NCCN intermediate risk. 520 had treatment with Radical Prostatectomy (RP) (89 also with external beam-EBRT), 171 had EBRT (with or without HDR brachy), and 211 seed implant (SI). 226 had no treatment (NT) in the first 12 m. 52.5% managed in public hospitals, rest private. Univariate analysis: UB associated with management type, and hospital type, and RB and SB associated with these factors, as well as age and disease stage. On multivariate regression SB at 12 m was associated with increasing age (p=0.002) and radical treatment types (RP and EBRT/HDR, p<0.001 and 0.003 respectively)—except SI—compared to NT; RB was associated with SI (0.02) and EBRT/HDR (0.007) and treatment in a public hospital (0.006); and UB was associated with public hospital (<0.001). All associations at 12 m remained significant at 24 m. SF12 physical score had a positive association with RP vs NT (0.014), hospital type (0.001) and younger age. SF12 mental health also showed associations. Conclusions: A large scale registry in Australia assessing patient-reported quality of life outcomes after prostate cancer treatment shows patterns similar to that seen in North American reports.


Sign in / Sign up

Export Citation Format

Share Document